Connect to share and comment

Regeneron, Sanofi asthma drug seen as potential game changer

By Ransdell Pierson (Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.

UPDATE 1-Affymax, Takeda recall anemia drug Omontys after deaths

TOKYO/WASHINGTON, Feb 24 (Reuters) - U.S.-based Affymax Inc and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anemia treatment Omontys (peginesatide) in the United States due to reports of serious hypersensitivity reactions, including some deaths. As of Sunday, fatal reactions to the injection have been reported in about 0.02 percent of 25,000 patients after receiving their initial injection of the treatment, Affymax said in a statement.
Syndicate content